VASCULAR SURGERY: REVIEW

 

The future of HIV vasculopathy when our patients are on antiretroviral therapy

 

 

Renald Barry

M.MED., Department of Surgery, University of the Free State, Bloemfontein

 

 

---

SUMMARY

South Africa was one of the last countries in Africa to be affected by the HIV epidemic, but currently has one of the highest prevalences in the world. Antiretroviral therapy (ART) was recently introduced in South Africa, and as of December 2007 antiretroviral treatment coverage in this country was about 25% (UNAIDS, 2008). There is a well-documented relationship between vascular disease and HIV infection. This HIV vasculopathy may manifest as arterial aneurysms, occlusive disease or complications of hypercoagulability. The question to be asked is 'What is the future of HIV vasculopathy when our patients are on antiretroviral therapy?'

---

 

“Full text available only in PDF format”

 

REFERENCES

1. Report on the global AIDS epidemic: executive summary. 2008. www.unaids.org (accessed 23 December 2008).         [ Links ]

2. Yeni PG, Hammer SM, Hirsh MS, et al. Treatment of adult HIV infection: 2004 recommendations of the International AIDS Society - USA Panel. JAMA 2004; 292: 251-265.         [ Links ]

3. Sterling TR, Chaisson RE, Moore RD. Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm³: disease progression, treatment durability, and drug toxicity. Clin Infect Dis 2003; 36: 812-815.         [ Links ]

4. Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995; 332: 693-699.         [ Links ]

5. Masur H. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. N Engl J Med 1993; 329: 898-904.         [ Links ]

6. Gulick R, Mellors J, Havlir D, et al. Potent and sustained antiretroviral activity of indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC). In: Supplement to the XI International Conference on AIDS, Vancouver, BC (7-12 July 1996). Vancouver, BC: XI International Conference on AIDS Society, 1996: 19. abstract.         [ Links ]

7. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-733.         [ Links ]

8. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-860.         [ Links ]

9. Guillevin L. Virus-induced systemic vasculitides: new therapeutic approaches. Clin Dev Immunol 2004; 11: 227-231.         [ Links ]

10. Venter WDF, Sanne IM. The cardiovascular consequences of HIV and antiretroviral therapy. Cardiovasc J S Afr 2003; 14: 225-229.         [ Links ]

11. Law M, Friis-Moller N, Weber R, et al. DAD Study Group. Modelling the three year risk of myocardial infarction among participants in the D:A:D study. HIV Med 2003; 4: 1-10.         [ Links ]

12. Matetzky S, Domingo M, Kar S, et al. Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med 2003; 163: 457-460.         [ Links ]

13. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003 (Erratum, N Engl J Med 2004; 350: 955).         [ Links ]

14. Hammer SM. Management of newly diagnosed HIV infection. N Engl J Med 2005; 353: 1702-1710.         [ Links ]